Not all immunotherapies are created equal.

In this episode of Outsmart Cancer, Dr. Dino Prato, founder of Envita Medical Centers, compares TILs (Tumor-Infiltrating Lymphocytes) with AAIT (Autologous Adoptive Immunotherapy) — two powerful immune-based approaches designed to help the body fight cancer.

While TILs are extracted from the tumor and reactivated before being reinfused, AAIT starts with fresh, healthy natural killer (NK) cells and dendritic cells taken from the blood. These are trained using danger signals (DAMPs) and tumor antigens to recognize and destroy cancer cells more effectively.

🎯 What You’ll Learn in This Episode:

• The difference between TILs and AAIT in mechanism and safety
• Why TIL therapy often causes immune exhaustion and side effects
• How AAIT uses dendritic cells and DAMPs to “teach” the immune system
• Why NK cells can cross the blood-brain barrier and attack hidden tumors
• How making “cold” tumors “hot” improves immunotherapy results
• Why Envita focuses on immune retraining rather than single-shot therapy

📊 Dr. Prato explains how fresh, personalized immune cell therapies may help patients avoid the severe reactions sometimes seen with TILs while maintaining strong, targeted immune function.

“Your immune system is your army — the key is training it to win.”

Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at:

https://www.scirp.org/journal/paperinformation?paperid=132493